Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM
10:40am, Sunday, 18'th Jul 2021
NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM). Such investors are ad
Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag
11:35am, Thursday, 15'th Jul 2021
The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM
10:08pm, Wednesday, 14'th Jul 2021
NEW YORK, July 14, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ("Axsome" or the "Company") (NASDAQ: AXSM). Such investors are a
Why Shares of Axsome Therapeutics Are Falling Today
04:32pm, Wednesday, 14'th Jul 2021
The FDA took back a beneficial designation but management isn't changing its plans.
Buy This Stock Before Everyone Else Does
09:12am, Wednesday, 14'th Jul 2021
This biotech has significant upside left.
What's Next For Axsome Therapeutics Stock After A 13% Rise In A Month?
10:00am, Monday, 21'st Jun 2021
The stock price of Axsome Therapeutics, a biopharmaceutical company focused on developing novel therapies for central nervous system conditions, has seen a 13% rise over the last twenty-one trading se
Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022
09:01am, Wednesday, 16'th Jun 2021
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.
Axsome Therapeutics Targets Submission Of US Application For Fibromyalgia Candidate By 2022
09:34am, Tuesday, 15'th Jun 2021
After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14 to manage fibromyalgia. The submission
2 Top Biotech Stocks to Buy for Summer 2021
06:31am, Saturday, 05'th Jun 2021
Progress in these companies' drug development pipelines should give shareholders plenty to look forward to.
Axsome Therapeutics: PDUFA Ahead
08:06am, Thursday, 03'rd Jun 2021
Axsome has a PDUFA on August 22.
Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus
12:02pm, Tuesday, 11'th May 2021
Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q1 2021 Results - Earnings Call Transcript
12:52pm, Monday, 10'th May 2021
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q1 2021 Results - Earnings Call Transcript
Why Earnings Season Could Be Great for Axsome Therapeutics (AXSM)
09:46am, Friday, 07'th May 2021
Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) is joining Mental Health America (MHA) and other advocacy organizations in observing May is Mental Health Month, by
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today
02:18pm, Monday, 26'th Apr 2021
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQ
